Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase.
Pavlů
Jirí
J
Department of Haematology, Imperial College at Hammersmith Hospital, London, United Kingdom. jiri.pavlu@imperial.nhs.uk
Kew
Andrea K
AK
Taylor-Roberts
Beatrice
B
Auner
Holger W
HW
Marin
David
D
Olavarria
Eduardo
E
Kanfer
Edward J
EJ
MacDonald
Donald H
DH
Milojkovic
Dragana
D
Rahemtulla
Amin
A
Rezvani
Katayoun
K
Goldman
John M
JM
Apperley
Jane F
JF
Szydlo
Richard M
RM
D000293:Adolescent; D000328:Adult; D002097:C-Reactive Protein / Q000378:metabolism; D002648:Child; D015897:Comorbidity; D005260:Female; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology; D018579:Patient Selection; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D015996:Survival Rate; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
D002097:C-Reactive Protein